Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

118.61 +3.32 (+2.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,206,339
Open 115.02
Bid (Size) 114.90 (2)
Ask (Size) 119.97 (2)
Prev. Close 115.29
Today's Range 114.66 - 118.77
52wk Range 110.03 - 238.00
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment. 
Via Benzinga

Performance

YTD
-20.9%
-20.9%
1 Month
-17.1%
-17.1%
3 Month
-16.0%
-16.0%
6 Month
-37.4%
-37.4%
1 Year
-38.3%
-38.3%

More News

Read More
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
From Biogen Inc.
Via GlobeNewswire
How Is The Market Feeling About Biogen?
Via Benzinga
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
What 14 Analyst Ratings Have To Say About Biogen
Via Benzinga
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Via Benzinga
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Via The Motley Fool
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
From Biogen Inc.
Via GlobeNewswire
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Via Benzinga
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
From Biogen Inc.
Via GlobeNewswire
Indexes Swimming In Red Ink On Recession Fears
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
Via Benzinga
Stocks Plummet As Trade Partners Retaliate Against Tariffs
Via Talk Markets
Topics Government Stocks / Equities World Trade
Exposures Political Tariff
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Via StockStory
Synchronicity: Denying The Unexplainable
Via Talk Markets
Topics Stocks / Equities
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Via Benzinga
Biogen Stock Is Mutating Into a Value Play
Via MarketBeat
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Via Benzinga

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 118.61
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 04/17/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 17.29B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 17B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.